AIM ImmunoTech (AIM) Net Cash Flow (2010 - 2026)
AIM ImmunoTech's (AIM) quarterly Net Cash Flow came in at $2.8 million in Q1 2026, up 452.55% YoY from $512349.1 in Q1 2025, and up 343.73% on a QoQ basis from $638000.0 in Q4 2025.
AIM ImmunoTech (AIM) Net Cash Flow (2010 - 2026) Analysis & Trends
AIM ImmunoTech (AIM) has 17 years of Net Cash Flow data on file, last reported at $2.8 million in Q1 2026.
- Quarterly Net Cash Flow rose 452.55% year-over-year to $2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.9 million (up 305.17% YoY) and the FY2025 annual result came in at $1.3 million, up 134.35% from the prior year.
- Net Cash Flow rose to $2.8 million in Q1 2026, from $638000.0 in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $5.4 million in Q2 2022 to a low of -$9.8 million in Q4 2023.
- A 5-year average of -$1.5 million and a median of -$2.1 million in 2024 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2023 — Net Cash Flow tumbled 263.08% — and 2026, when it jumped 452.55%.
- Tracing AIM's Net Cash Flow over 5 years: stood at -$2.7 million in 2022, then plunged by 263.08% to -$9.8 million in 2023, then jumped by 108.0% to $786000.0 in 2024, then slipped by 18.83% to $638000.0 in 2025, then surged by 343.73% to $2.8 million in 2026.
- The last three Net Cash Flow figures came in at $2.8 million (Q1 2026), $638000.0 (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 65.11 Bn | 59.92 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.73 Bn | 50.59 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.64 Bn | 28.33 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.32 Bn | 26.49 Bn | - | 225.59 Mn |
| 10 | AIM ImmunoTech | 4.51 Mn | -5.45 Mn | 21,000.00 | 4.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.08 Mn |
| Jun 30, 2026 | 4.08 Mn |
| Mar 31, 2026 | 2.83 Mn |
| Mar 31, 2026 | 2.83 Mn |
| Dec 31, 2025 | 638,000.00 |
| Dec 31, 2025 | 638,000.00 |
| Sep 30, 2025 | 1.87 Mn |
| Sep 30, 2025 | 1.87 Mn |
| Jun 30, 2025 | -422,000.00 |
| Jun 30, 2025 | -422,000.00 |
| Mar 31, 2025 | -803,000.00 |
| Mar 31, 2025 | -803,000.00 |
| Dec 31, 2024 | 786,000.00 |
| Dec 31, 2024 | 786,000.00 |
| Sep 30, 2024 | -2.64 Mn |
| Sep 30, 2024 | -2.64 Mn |
| Jun 30, 2024 | 259,000.00 |
| Jun 30, 2024 | 259,000.00 |
| Mar 31, 2024 | -2.14 Mn |
| Mar 31, 2024 | -2.14 Mn |